MAP2 protein aptamer WQY-002 and its application
The MAP2 protein aptamer WQY-002, obtained through MB-SELEX screening, fills the technological gap in MAP2 protein aptamers, achieving high specificity and high affinity, and is suitable for applications such as biological detection and new drug development.
Patent Information
- Application Number
- CN202410010221.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-04
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-01-04
AI Technical Summary
The lack of MAP2 protein nucleic acid aptamers in existing technologies has created a technological gap in its applications in biological detection, in vitro diagnostics, biomarker detection, and new drug development.
A MAP2 protein nucleic acid aptamer WQY-002 and its derivatives are provided. They were screened by MB-SELEX technology, and the affinity constant KD of WQY-002 with MAP2 protein was found to be approximately 26.6 nM by magnetic bead fluorescence quantitative PCR. WQY-002 can be modified and labeled to improve its application effect.
The MAP2 protein nucleic acid aptamer WQY-002 exhibits high specificity and affinity, small molecular weight, high sensitivity, good stability, and is easy to synthesize, filling the gap in MAP2 protein nucleic acid aptamers and is suitable for fields such as biosensors, in vitro diagnostics, and new drug development.
Smart Images

Figure CN118374501B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedicine, and more specifically relates to a MAP2 protein nucleic acid aptamer WQY-002 and its applications. Background Technology
[0002] An aptamer is an oligonucleotide sequence (DNA or RNA). It is typically synthesized artificially from a nucleic acid library using an in vitro screening technique—Systematic evolution of ligands by exponential enrichment (SELEX). Aptamers possess a stable secondary structure and can specifically bind to target molecules. Like antibodies, aptamers exhibit strong recognition capabilities and high affinity for their binding ligands. Target molecules that aptamers can bind to include small molecules, proteins, bacteria, viruses, cells, and tissues.
[0003] In traditional antigen-antibody reactions, proteins, as probe molecules, are easily denatured by environmental factors such as pH and temperature, and their synthesis is expensive. Nucleic acid aptamers, composed of DNA or RNA, are smaller than proteins. After SELEX enrichment, they exhibit sensitivity comparable to antigen-antibody reactions, are easier to synthesize, and have better stability than proteins. Currently, there are no reports on MAP2 protein nucleic acid aptamers, either domestically or internationally. Summary of the Invention
[0004] In view of the above problems, this application provides a MAP2 protein nucleic acid aptamer WQY-002 and its application, in order to fill the technical gap of the lack of MAP2 protein nucleic acid aptamers in the prior art, and at the same time provide basic support for the subsequent application of MAP2 protein nucleic acid aptamers as molecular probes to construct biological detection sensors, in vitro diagnostics, detection and analysis of biomarkers, new drug development and other applications.
[0005] To achieve the above objectives, the present invention provides a MAP2 protein nucleic acid aptamer WQY-002, the nucleotide sequence of which is shown in SEQ ID NO.1.
[0006] SEQ ID NO. 1 is TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0007] In one specific embodiment, the nucleotide sequence of the MAP2 protein aptamer WQY-002 is obtained by modifying the nucleotide sequence shown in SEQ ID NO.1.
[0008] In some specific embodiments, the modification includes at least one of the following modification methods: phosphorylation, methylation, amination, thiolation, isotopization, and fluorination.
[0009] On the other hand, the present invention provides a derivative of the MAP2 protein nucleic acid aptamer, the derivative of the MAP2 protein nucleic acid aptamer comprising the MAP2 protein nucleic acid aptamer shown in SEQ ID NO.1 and a detectable marker labeling the MAP2 protein nucleic acid aptamer.
[0010] The label can be formed by chemical bonding or physical adsorption.
[0011] In some preferred embodiments, the detectable marker includes at least one of fluorescent markers, radioactive substances, therapeutic substances, biotin, avidin, enzymes, digoxigenin, luminescent nanomaterials, magnetic beads, colloidal gold, colored glass, plastic beads, small molecule peptides, and siRNA.
[0012] Fluorescent markers include, but are not limited to, FAM (Carboxyfluorescein), FITC (Fluorescein isothiocyanate), TET (Tetrachlorofluorescein), HEX (Hexachlorofluorescein), JOE (2,7-dimethyl-4,5-dichloro-6-carboxyfluorescein), rhodamine dyes (such as R110, TAMRA, Texas Red, etc.), ROX, AlexaFluor dyes (such as Alexa 350, Alexa 405), and ATTO dyes (such as ATTO 390, ATTO 425, ATTO...). 465), DyLight dyes, cyanine dyes (such as Cy2, Cy3, Cy5.5, Cy7, Cy7.5), FluoProbes dyes, SulfoCy dyes, Seta dyes, IRIS dyes, SeTau dyes, SRfluor dyes, Square dyes.
[0013] Radioactive materials include, for example, 3H, 14C, 32P, 33P, 35S, 90Y, 99Tc, 111In, 125I, 131I, 177Lu, 166Ho, and 153Sm.
[0014] Therapeutic substances, biotin, avidin, enzymes, digoxin, luminescent nanomaterials, magnetic beads, colloidal gold, colored glass, plastic beads, small molecule peptides, and siRNA.
[0015] In addition, the present invention provides a detection kit comprising the MAP2 protein nucleic acid aptamer shown in SEQ ID NO.1 or a detectable marker that labels the MAP2 protein nucleic acid aptamer shown in SEQ ID NO.1.
[0016] Detectable markers can emit detectable signals, including optical signals or electrical signals. Optical signals include fluorescence signals, light absorption signals, infrared absorption signals, Raman scattering signals, or chemiluminescence signals.
[0017] The present invention also provides a pharmaceutical component comprising the MAP2 protein nucleic acid aptamer shown in SEQ ID NO.1 or the MAP2 protein nucleic acid aptamer modified by one of the following modification methods: phosphorylation, methylation, amination, thiolation, isotopization and fluorination, or a MAP2 protein nucleic acid aptamer derivative formed by the MAP2 protein nucleic acid aptamer shown in SEQ ID NO.1 and a detectable marker labeled thereon.
[0018] Furthermore, the present invention also provides a MAP2 protein nucleic acid aptamer biosensor, comprising the steps of immobilizing the MAP2 protein nucleic acid aptamer shown in SEQ ID NO. 1 or the MAP2 protein nucleic acid aptamer modified by one of the following modification methods: phosphorylation, methylation, amination, thiolation, isotopization and fluorination, onto an electrode, nanomaterial or thin film to obtain the biosensor.
[0019] The target of this invention is the MAP2 protein. Specifically, the MAP2 protein nucleic acid aptamer was screened using the MB-SELEX (magnetic bead-exponential enrichment ligand system evolution technique) method, which uses carboxyl magnetic beads to fix the target. The aptamer was named WQY-002. The affinity constant KD between the screened nucleic acid aptamer and the MAP2 protein was measured by the magnetic bead fluorescence quantitative PCR method, which was approximately 26.6 nM.
[0020] The nucleotide sequence of WQY-002 is shown in SEQ ID No. 1, SEQ ID No. 1: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0021] Unlike existing technologies, the MAP2 protein aptamer provided by the above technical solution exhibits high specificity and affinity for the MAP2 protein, filling the gap in nucleic acid aptamers targeting the MAP2 protein. Compared with antibodies, it has advantages such as small molecular weight, high sensitivity, good stability, and ease of synthesis and modification. The above description of the invention is merely an overview of the technical solution of this application. To enable those skilled in the art to better understand the technical solution of this application and to implement it based on the content described in the specification and drawings, and to make the above-mentioned objectives and other objectives, features, and advantages of this application easier to understand, the following description is provided in conjunction with specific embodiments and accompanying drawings. Attached Figure Description
[0022] The accompanying drawings are only used to illustrate the principles, implementation methods, applications, features, and effects of specific embodiments of this application and other related content, and should not be considered as limitations on this application.
[0023] In the accompanying drawings of the instruction manual:
[0024] Figure 1 This is a flowchart illustrating the fixed target screening method used in a specific embodiment of the present invention;
[0025] Figure 2 The results of the MAP2 protein screening retention rate calculation in a specific embodiment of the present invention are as follows;
[0026] Figure 3 Detailed implementation of protein coupling detection results;
[0027] Figure 4 The results of DNA sequence flow through channel three in the specific implementation method;
[0028] Figure 5 The results of DNA sequence flow through channel four in the specific implementation method;
[0029] Figure 6 The detection results are the difference between channel four and channel three in the specific implementation method;
[0030] Figure 7 This is a numerical diagram showing the binding of the MAP2 protein to the DNA sequence.
[0031] Figure 8 The image shows the detection results of DNA sequence #2 flowing through channel three;
[0032] Figure 9 The image shows the detection results of DNA sequence #2 flowing through channel four;
[0033] Figure 10 The detection results are shown in the image below, representing the difference between channel four and channel three.
[0034] Figure 11 The graph shows the KD fitting data for DNA sequence detection of #2. Detailed Implementation
[0035] To illustrate the possible application scenarios, technical principles, implementable specific solutions, and achievable objectives and effects of this application in detail, the following description, in conjunction with the listed specific embodiments and accompanying drawings, provides a detailed explanation. The embodiments described herein are merely illustrative of the technical solutions of this application and are therefore intended to limit the scope of protection of this application.
[0036] In this document, the term "embodiment" means that a specific feature, structure, or characteristic described in connection with an embodiment may be included in at least one embodiment of this application. The term "embodiment" appearing in various places throughout the specification does not necessarily refer to the same embodiment, nor does it specifically limit its independence or connection with other embodiments. In principle, in this application, as long as there are no technical contradictions or conflicts, the technical features mentioned in each embodiment can be combined in any way to form corresponding implementable technical solutions.
[0037] Unless otherwise defined, the technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains; the use of related terms herein is merely for the purpose of describing particular embodiments and is not intended to limit this application.
[0038] In the description of this application, the term "and / or" is used to describe the logical relationship between objects, indicating that three relationships can exist. For example, A and / or B means: A exists, B exists, and A and B exist simultaneously. Additionally, the character " / " in this document generally indicates that the preceding and following objects have an "or" logical relationship.
[0039] Unless otherwise specified, the use of terms such as “comprising,” “including,” “having,” or other similar expressions in this application is intended to cover non-exclusive inclusion, which does not exclude the presence of additional elements in a process, method, or product that includes the stated elements, such that a process, method, or product that includes a list of elements may include not only those defined elements but also other elements not expressly listed, or elements inherent to such a process, method, or product.
[0040] As understood in the Examination Guidelines, in this application, expressions such as "greater than," "less than," and "exceeding" are understood to exclude the stated number; expressions such as "above," "below," and "within" are understood to include the stated number. Furthermore, in the description of the embodiments in this application, "multiple" means two or more (including two), and similar expressions related to "multiple" are also understood in this way, such as "multiple groups" and "multiple times," unless otherwise explicitly specified.
[0041] In this invention, the terms "MAP2", "MAP-2", and "Map2" have the same meaning. When the above expressions appear, they all refer to the target protein of this invention and can be used interchangeably.
[0042] Unless otherwise specified, the experimental methods used in the following examples are conventional methods or are performed according to the conditions recommended by the manufacturer; unless otherwise specified, the materials and reagents used in the examples are conventional biochemical reagents that are commercially available.
[0043] The experimental materials used in the following examples were sourced from the following sources:
[0044] 1) Dynabeads™ MyOne™ carboxylic acid magnetic beads (purchased from Thermo, item number: 65011);
[0045] 2) DPBS buffer: (pH 7.2~7.4): 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, 1 mM CaCl2, 0.5 mM MgCl2;
[0046] 3) Library: lib18-76nt: 20 bases each for the two primers, and 36 bases for the random region in the middle.
[0047] 5'-3'
[0048] TCCAGCACTCCACGCATAACNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNGTTATGCGTGCTACCGTGAA;
[0049] 4) Corresponding library qPCRmix;
[0050] 5) Corresponding library ePCRmix;
[0051] 6) SELEX Single-Chain Preparation Kit (Long and Short Chain Method) (purchased from Aptamy, catalog number: SEP-201903);
[0052] 7) ePCR microdroplet generation oil (purchased from Aptamy, catalog number: EPO-100);
[0053] 8) MAP2 protein (MCEMETAP2 / Methionine aminopeptidase 2 protein, Human(Sf9,His));
[0054] 9) HIS small peptide (9 histidine residues);
[0055] 10) EDC (0.4M 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, purchased from Sigma-Aldrich, catalog number: 800907).
[0056] 11) NHS (0.1M N-hydroxysuccinimide, purchased from Sigma-Aldrich, catalog number: 130672).
[0057] 12) pH 8.5 1M ethanolamine;
[0058] 13) Primer information:
[0059]
[0060] Example 1
[0061] MAP2 protein aptamer WQY-002 and its preparation
[0062] The nucleotide sequence of WQY-002 is shown in SEQ ID No. 1, SEQ ID No. 1: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0063] Please see Figure 1 The flowchart for fixed target screening shown is followed by the following steps:
[0064] 1. Immobilization of positive screening targets (MAP2 protein) and negative screening targets (HIS small peptides) with carboxyl magnetic beads.
[0065] 1.1 Preparation of Positive Sieve Magnetic Beads (MAP2 Protein)
[0066] 1) Take 50ul of carboxyl magnetic beads, wash them 4 times with 200ul of H2O, use a magnet to hold the magnetic beads, and remove the supernatant.
[0067] 2) Take 50 μL of prepared NHS and 50 μL of EDC, thaw slowly at room temperature, add NHS to EDC and mix well, then add to the magnetic beads from the previous step. Incubate on a shaker at room temperature for 25 minutes. (If the magnetic beads clump together during this time, shake occasionally to mix them well). Use a magnet to hook the magnetic beads, remove the supernatant, and quickly wash once with 200 μL of H2O.
[0068] 3) Take 30 μL of MAP2 protein (concentration 0.33 mg / mL), add 170 μL of pH 3.6 10 mM sodium acetate solution, mix well, and add to the magnetic beads from the previous step. Incubate on a shaker at room temperature for 60 min. (If the magnetic beads aggregate during this time, shake occasionally.) Use a magnet to catch the magnetic beads, remove the supernatant, and wash once quickly with 200 μL of H2O.
[0069] 4) Add 100 μL of 1M pH 8.5 ethanolamine to the magnetic beads from the previous step and incubate at room temperature on a shaker for 25 min. (If the magnetic beads aggregate during this time, shake occasionally to mix them.) Use a magnet to pick up the magnetic beads, discard the supernatant, and wash four times with 200 μL of DPBS. After washing, add 50 μL of DPBS to store the magnetic beads for later use, and label them MB-MAP2.
[0070] 1.2 Preparation of reverse screening magnetic beads (HIS small peptide)
[0071] 1) Take 50ul of carboxyl magnetic beads, wash them 4 times with 200ul of H2O, use a magnet to hold the magnetic beads, and remove the supernatant.
[0072] 2) Take 50 μL of prepared NHS and 50 μL of EDC, thaw slowly at room temperature, add NHS to EDC and mix well, then add to the magnetic beads from the previous step. Incubate on a shaker at room temperature for 25 minutes. (If the magnetic beads clump together during this time, shake occasionally to mix them well.) Use a magnet to fish out the magnetic beads, remove the supernatant, and quickly wash once with 200 μL of H2O.
[0073] 3) Take 10 μL of HIS9 peptide (concentration 1 mg / mL), add 190 μL of pH 4.5 10 mM sodium acetate buffer, mix well, and add to the magnetic beads from the previous step. Incubate on a shaker at room temperature for 40 min. (If the magnetic beads aggregate during this time, shake occasionally.) Use a magnet to catch the magnetic beads and discard the supernatant.
[0074] 4) Add 100 μL of 1M pH 8.5 ethanolamine to the magnetic beads from the previous step and incubate at room temperature on a shaker for 25 min. (If the magnetic beads aggregate during this time, shake occasionally to mix them.) Use a magnet to pick up the magnetic beads, discard the supernatant, and wash four times with 200 μL of DPBS. After washing, add 50 μL of DPBS to store the magnetic beads for later use, and label them MB-HIS.
[0075] 2. Magnetic bead screening process (first round without reverse screening, no step 3) -- step 11)
[0076] 1) Take one lib18-76bp library, centrifuge at 12000rpm*10min, add 280ul DPBS to dissolve, dilute the library to a final concentration of 5uM280ul, and aliquot into PCR tubes.
[0077] 2) After centrifuging the PCR tubes containing the library at low speed, place them in a PCR instrument for slow renaturation. The program is: 95℃ for 10 min, 4℃ for 5 min, and 25℃ for 10 min.
[0078] 3) Add the library with good refoldability from the previous step to 50 μL of MB-HIS, mix slowly by pipetting, and incubate on a shaker at room temperature for 60 min.
[0079] 4) Use a magnet to fish for magnetic beads, and use the gun tip to attract the clear water. This is called pool-.
[0080] 5) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place, and label the supernatant as wash1-.
[0081] 6) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash2-.
[0082] 7) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash3-.
[0083] 8) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash4-.
[0084] 9) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash5-.
[0085] 10) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash6-.
[0086] 11) Add 200 μL of DPBS to the magnetic beads and boil them in a water bath for 10 minutes. Use a magnet to hold the magnetic beads in place and record the supernatant as solution by MB-HIS.
[0087] 12) Add pool- to 50ul MB-MAP2, mix slowly with a pipette, and incubate on a shaker at room temperature for 60min.
[0088] 13) Use a magnet to fish for magnetic beads and remove the supernatant.
[0089] 14) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash1+.
[0090] 15) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash2+.
[0091] 16) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash3+.
[0092] 17) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash4+.
[0093] 18) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash5+.
[0094] 19) Rinse the magnetic beads with 200 μL DPBS, using a magnet to hold the magnetic beads in place. The supernatant is labeled as wash6+.
[0095] 20) Add 200 μL of DPBS to the magnetic beads and boil them in a water bath for 10 minutes. Use a magnet to hold the magnetic beads in place and record the supernatant as solution by MB-MAP2.
[0096] 21) Take an 8-tube Roche PCR tube, add 30 μL of qPCR mix to each well, then add 2 μL each of wash and elution, and perform quantitative real-time PCR. The program is as follows: 95℃ for 2 min; 95℃ for 0.5 min, 60℃ for 0.5 min, 72℃ for 0.5 min, 30 cycles.
[0097] 3. Preparation of single-stranded library ssDNA
[0098] 1) Add the remaining elution by MB-MAP2 to 2ml of ePCRmix and mix well.
[0099] 2) Aliquot the prepared mixture into PCR tubes, 100 μL per tube, and perform PCR for 25 cycles. The program is: 95℃ for 2 min; 95℃ for 0.5 min, 60℃ for 0.5 min, 72℃ for 0.5 min, 25 cycles;
[0100] 3) Recover the PCR products.
[0101] 4) Concentrate PCR products with n-butanol.
[0102] 5) Denaturing PAGE electrophoresis separates single strands.
[0103] 6) Concentrate ssDNA to approximately 100 μL with n-butanol.
[0104] 7) Dialyze ssDNA overnight with a 3.5KD micro-nucleic acid dialysis membrane and DPBS buffer. After measuring the concentration with a micro-UV light, label the prepared ssDNA as pool 1 for the next round of screening.
[0105] 4. Calculate the retention rate of forward and reverse sieves.
[0106] Retention rate was calculated based on qPCR results. The method involved diluting the library to different concentrations using known concentrations and performing qPCR. A standard curve was then constructed using the concentrations and corresponding Cq values. The Cq values of the wash and elution samples were then substituted into the standard curve to calculate the number of molecules.
[0107] The retention rate is the ratio of the number of molecules in the library that bind to the target or the reverse screening target obtained in each round of screening to the total number of library sequences input. The retention rate verification results for the six rounds of screening are as follows: Figure 2 As shown, the fluorescence quantitative PCR curve of the 6th round of screening increased, and the retention rate of positive screening was higher than that of reverse screening, which means that high-throughput sequencing can be performed.
[0108] 5. Multiple rounds of screening
[0109] Following the above steps, a total of 6 rounds of screening are conducted. The general screening process is similar, and the differences between each round are listed in the table below. The screening criteria for each round are shown in Table 1.
[0110] Table 1. Screening criteria for rounds one through six
[0111]
[0112] 6. Preparation of sequencing samples for each round of sequencing of libraries obtained from MAP2 protein immobilization target screening and high-throughput sequencing.
[0113] 6.1 Experimental Materials and Methods (including samples)
[0114] 1) Prepare a PCR mix for sequencing samples, in which the forward primers are replaced with forward primers with different tags, and the reverse primers are primers without any modifications;
[0115] 2) Library information: lib 18-76bp full length 76bp, random region 36bp;
[0116] 3) Libraries obtained from screening MAP2 protein immobilization targets;
[0117] 4) UNIQ-10 oligonucleotide purification kit (purchased from Shanghai Sangon Biotech, catalog number: B511143);
[0118] 5) Anhydrous ethanol
[0119] 6) TE buffer (10mmol / L Tris.HCl; 1mmol / L EDTA; pH7.8-8.2)
[0120] 6.2 Experimental Procedure and Results
[0121] 1) Using each round of libraries as templates, 20 μL of each 500 nM library was added to 400 μL of a PCR mix with different barcodes (the barcode information for different libraries is shown in the table below). PCR amplification was performed using the following program: 95°C pre-denaturation for 1 min, 95°C denaturation for 30 s, 60°C annealing for 30 s, and 72°C extension for 30 s, for a total of 20 cycles. The tag primer information for the sequencing sample libraries is shown in Table 2.
[0122] Table 2. Tag and primer information for sequencing sample libraries
[0123]
[0124] 2) After amplification, concentration and purification were performed. The amplified double strands were recovered using the UNIQ-10 oligonucleotide purification kit from Shanghai Sangon Biotech. The amplified product was first adsorbed onto the column with high salt, followed by low salt elution. The detailed steps of washing and elution are as follows: After amplification, all samples were mixed and aliquoted into 15ml centrifuge tubes, and n-butanol was added to concentrate to 200uL.
[0125] 3) The standard extraction procedure was followed to recover dsDNA using the UNIQ-10 oligonucleotide purification kit (Shanghai Sangon Biotech B511143). The specific procedures are as follows:
[0126] Adjust the volume of the solution containing the DNA fragment to 50–100 µl using TE Buffer, then add 10 times the volume of Binding Buffer I and mix well. (If purifying oligonucleotide fragments containing radiolabeled molecules, please treat any radioactively contaminated Binding Buffer I, Wash Solution, purification kit, pipette tips, centrifuge tubes, etc., with special care to avoid environmental contamination.)
[0127] Transfer the mixture to the adsorption column, incubate at room temperature for 2 minutes, and centrifuge at 8000 rpm for 2 minutes. Discard the liquid in the collection tube and place the adsorption column into the same collection tube.
[0128] Add 500 µl of Wash Solution to the adsorption column and centrifuge at 10,000 rpm for 1 min. (Please check that the correct amount of anhydrous ethanol has been added to the Wash Solution before first use.)
[0129] Repeat the above once.
[0130] Discard the waste liquid in the collection tube, place the adsorption column into the same collection tube, and centrifuge at 10,000 rpm for 2 minutes. This step is absolutely essential; otherwise, residual ethanol will severely affect the yield and subsequent experiments.
[0131] Place the adsorption column into a clean 1.5 ml centrifuge tube, add 30–50 µl of Elution Buffer to the center of the adsorption membrane, incubate at room temperature for 5 min, and centrifuge at 12,000 rpm for 1 min. Store the obtained DNA solution at -20°C or use it for subsequent experiments. (The Elution Buffer is 2.5 mM Tris-HCl, pH 8.5, which can be replaced with TE or water (pH > 7.0); preheating the Elution Buffer to 60°C can further improve the yield; do not use less than 30 μl of elution buffer for elution).
[0132] 4) High-throughput sequencing was performed using the Illumina-NovaSeq 6000 sequencing system platform.
[0133] 5) After the RAW data obtained from sequencing is extracted into an Excel document, the sequences are analyzed, and the selected sequences are synthesized and their affinity is tested.
[0134] 7. Affinity detection of candidate DNA sequences obtained from MAP2 protein immobilization target screening
[0135] 7.1 Experimental materials (including samples)
[0136] 1) Candidate DNA sequences obtained from MAP2 protein immobilization target screening;
[0137] 2) CM5 sensor chip (purchased from Cytiva, part number 29149604);
[0138] 3) MAP2 protein (MCE METAP2 / Methionine aminopeptidase 2 protein, Human (Sf9, His));
[0139] 4) HIS small peptide (9 histidine residues);
[0140] 5) EDC (0.4 M 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, purchased from Sigma-Aldrich, catalog number: 800907).
[0141] 6) NHS (0.1M N-hydroxysuccinimide, purchased from Sigma-Aldrich, catalog number: 130672).
[0142] 7) pH 8.5 1M ethanolamine.
[0143] 7.2 Experimental Procedure
[0144] 1) Protein coupling: The chip was activated by injecting the activation mixture solution to activate channels 3 and 4. The MAP2 protein was diluted to 15ug / ml with a 10mM sodium acetate aqueous solution at pH 3.6 and then injected into channel 4. The MAP2 protein coupling amount was 1794RU.
[0145] The HIS peptide was diluted to 25 ug / ml with a 10 mM sodium acetate aqueous solution at pH 4.5 and then injected into channel 3. The HIS peptide conjugation amount was 114 RU.
[0146] After the injection is completed, 1M pH 8.5 ethanolamine reagent is injected to block channels 3 and 4 at a flow rate of 10 μL / min for 10 min.
[0147] 2) The DNA sequences obtained from MAP2 protein immobilization target screening were diluted to 2 μM with DPBS before being analyzed. Specific experimental methods and parameter designs are shown in Table 3.
[0148] Table 3. Screening methods and parameters for MAP2 protein immobilization targets
[0149]
[0150] 7.3 Experimental Results
[0151] The results of protein coupling, DNA sequence flow through channel three, DNA sequence flow through channel four, and the detection results of channel four minus channel three are as follows: Figure 3 , Figure 4 , Figure 5 and Figure 6 As shown, FC=3 HIS peptide and FC=4 MAP2 protein.
[0152] The binding affinity numerical value of MAP2 protein to DNA sequence is as follows: Figure 7 As shown in Table 4.
[0153] Table 4. Affinity test data of MAP2 protein and candidate DNA sequences
[0154]
[0155] from Figure 7 As shown in Table 4, the DNA sequences screened by this invention do not bind to HIS peptides, exhibiting good specificity. DNA sequence #2 binds to MAP2 protein with a high binding value, and KD analysis was subsequently performed. Regeneration with 1M NaCl showed good results.
[0156] 8. KD detection of MAP2 protein and the screened DNA sequence #2.
[0157] 8.1 Experimental materials (including samples)
[0158] 1) Candidate DNA sequences obtained from MAP2 protein immobilization target screening;
[0159] 2) CM5 sensor chip (Cytiva part number 29149604);
[0160] 3) MAP2 protein (MCE METAP2 / Methionine aminopeptidase 2 protein, Human(Sf9,His));
[0161] 4) HIS small peptide (9 histidine residues);
[0162] 5) EDC (0.4M 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, purchased from Sigma-Aldrich, catalog number: 800907).
[0163] 6) NHS (0.1M N-hydroxysuccinimide, purchased from Sigma-Aldrich, catalog number: 130672).
[0164] 7) pH 8.5 1M ethanolamine;
[0165] 8) DPBS.
[0166] 8.2 Experimental Procedure
[0167] 1) Protein conjugation: The chip was activated by injecting the activation mixture into channels 3 and 4. The MAP2 protein was diluted to 10 μg / ml with a 10 mM sodium acetate aqueous solution at pH 3.6 and then injected into channel 4. The amount of MAP2 protein conjugated was 2399 Ru. The HIS peptide was diluted to 15 μg / ml with a 10 mM sodium acetate aqueous solution at pH 4.5 and then injected into channel 3. The amount of HIS peptide conjugated was 88 Ru.
[0168] After the injection is completed, 1M pH 8.5 ethanolamine reagent is injected to block channels 3 and 4 at a flow rate of 10 μL / min for 10 min.
[0169] 2) The DNA sequence #2 obtained from the MAP2 protein immobilization target screening was diluted to gradient concentrations with DPBS before being analyzed. The experimental parameters are shown in Table 5.
[0170] Table 5 Experimental methods and parameters
[0171]
[0172] #2 DNA sequence concentrations were diluted in the following gradients: 0 uM, 0.0078125 uM, 0.015625 uM, 0.03125 uM, 0.0625 uM, 0.125 uM, 0.25 uM, 0.5 uM, 1 uM, 2 uM.
[0173] 8.3 Experimental Results
[0174] The detection results of DNA sequence #2 flowing through channel three are as follows: Figure 8 As shown, the detection results of DNA sequence #2 flowing through channel four are as follows: Figure 9 As shown, the detection results of channel four difference minus channel three are as follows: Figure 10 As shown, the KD fitting data for DNA sequence detection #2 is as follows: Figure 11 As shown (KD≈26.6nM).
[0175] The experimental results above show that the control channel HIS peptide was coupled with 88 RU, the target channel MAP2 protein was coupled with 2399 RU, and the regeneration effect with 1M NaCl was good. The KD fitting value of DNA sequence #2 was KD≈26.6nM. The DNA sequence #2 was named WQY-002.
[0176] The nucleotide sequence of WQY-002 is shown in SEQ ID No. 1, SEQ ID No. 1: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0177] Example 2
[0178] The MAP2 protein aptamer was synthesized by phosphorylation modification of the following nucleotide sequence shown in SEQ ID No. 1: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0179] In other different embodiments, the MAP2 protein aptamer may also be obtained by modifying the nucleotide sequence shown in SEQ ID No. 1 with at least one of methylation, amination, thiolation, isotopization and fluorination.
[0180] Example 3
[0181] A derivative of the MAP2 protein aptamer is obtained by labeling the following nucleotide sequence shown in SEQ ID No. 1 with a detectable marker: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA. The above detectable marker is a fluorescent marker.
[0182] In other different embodiments, the derivative of the MAP2 protein aptamer is obtained by labeling the nucleotide sequence shown in SEQ ID No. 1 with at least one of the following as a detectable marker: radioactive material, therapeutic material, biotin, avidin, enzyme, digoxigenin, luminescent nanomaterial, magnetic beads, colloidal gold, colored glass, plastic beads, small molecule peptides, and siRNA.
[0183] Example 4
[0184] The test kit contains a nucleic acid aptamer WQY-002 with the following nucleotide sequence shown in SEQ ID No. 1: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0185] Example 5
[0186] The test kit contains a nucleic acid aptamer WQY-002, which is phosphorylated and modified with the following nucleotide sequence shown in SEQ ID No. 1: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0187] Example 6
[0188] The detection kit contains a nucleic acid aptamer WQY-002 modified with thiolation of the following nucleotide sequence shown in SEQ ID No. 1: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0189] In other different embodiments, the test kit may also comprise a nucleotide sequence represented by SEQ ID No. 1 modified by at least one of methylation, amination, isotopization and fluorination.
[0190] Example 7
[0191] The drug component comprises a nucleic acid aptamer WQY-002 with the following nucleotide sequence shown in SEQ ID No. 1: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0192] Example 8
[0193] The drug component comprises a nucleic acid aptamer WQY-002 obtained by thiolation modification of the following nucleotide sequence shown in SEQ ID No. 1: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0194] Example 9
[0195] The pharmaceutical component comprises a nucleic acid aptamer WQY-002 obtained by fluorination modification of the following nucleotide sequence shown in SEQ ID No. 1: TCCAGCACTCCACGCATAACTTCACGGTGTGTGCCCTTCACGGTTATGTGCTGGTCGTTATGCGTGCTACCGTGAA.
[0196] In other different embodiments, the pharmaceutical component may also comprise at least one modification of the nucleotide sequence shown in SEQ ID No. 1, namely phosphorylation, methylation, amination and isotopization.
[0197] Example 10
[0198] A MAP2 protein aptamer biosensor is prepared by immobilizing the MAP2 protein aptamer WQY-002 with the nucleotide sequence shown in SEQ ID No. 1 onto an electrode, nanomaterial, or thin film.
[0199] Example 11
[0200] A MAP2 protein aptamer biosensor is prepared by immobilizing a MAP2 protein aptamer obtained by modifying the nucleotide sequence shown in SEQ ID No. 1 onto an electrode, nanomaterial, or thin film.
[0201] Finally, it should be noted that although the above embodiments have been described in the text and drawings of this application, this should not limit the scope of patent protection of this application. Any technical solutions that are based on the essential concept of this application and utilize the content described in the text and drawings of this application, resulting in equivalent structural or procedural substitutions or modifications, as well as the direct or indirect application of the technical solutions of the above embodiments to other related technical fields, are all included within the scope of patent protection of this application.
Claims
1. A MAP2 protein nucleic acid aptamer, characterized in that, Its nucleotide sequence is shown in SEQ ID NO.
1.
2. A MAP2 protein nucleic acid aptamer, characterized in that, Its nucleotide sequence is obtained by modifying the nucleotide sequence of the MAP2 protein aptamer as described in claim 1.
3. The MAP2 protein aptamer according to claim 2, characterized in that, The modification includes at least one of the following modification methods: phosphorylation, methylation, amination, thiolation, isotopization, and fluorination.
4. A derivative of the MAP2 protein aptamer, characterized in that, It includes the MAP2 protein nucleic acid aptamer as described in claim 1 and a detectable marker that labels the MAP2 protein nucleic acid aptamer.
5. The derivative according to claim 4, characterized in that, The detectable markers include at least one of the following: fluorescent markers, radioactive substances, biotin, avidin, enzymes, digoxigenin, luminescent nanomaterials, magnetic beads, colloidal gold, colored glass, plastic beads, small molecule peptides, and siRNA.
6. A test kit, characterized in that, Includes the MAP2 protein nucleic acid aptamer as described in claim 1 or 2.
7. A MAP2 protein aptamer biosensor, characterized in that, The method includes the step of immobilizing the MAP2 protein nucleic acid aptamer as described in claim 1 or 2 onto an electrode, nanomaterial, or thin film.
Citation Information
Patent Citations
SE201903C1
Tau protein-binding DNA aptamers with capture / detection and therapeutic utilities in tauopathy-related neurodegenerative disorders
US20190101529A1
Biomarkers for traumatic brain injury
WO2015067915A1
